Life Sciences CLE Webinar Series
Haug Partners invites you to participate in our complimentary Life Sciences CLE Webinar Series.
During this quarterly program, thought-leaders will delve into key issues shaping intellectual property in biotechnology, pharmaceuticals, and medical devices in order to provide critical insights into patent strategies, regulatory developments, and litigation trends impacting the life sciences sector. Designed for legal professionals and industry leaders, this program ensures you’re prepared to navigate the rapidly evolving IP landscape. New York CLE credits will be available.
Designed for attorneys and professionals operating at the intersection of law and science, the program offers New York CLE credit and actionable takeaways to keep you ahead of the curve.
Have a topic you’d like us to cover? Use the form to the right or email [email protected] to propose topics, sign up for updates, and be the first to know about upcoming webinars.
Upcoming Session
The BPCIA at 15: A Data-Driven Retrospective on Biologics Patent Litigation
Presented by Andrew Wasson and Nick Giove
May 20, 2025 | 1:00 PM
On March 23, 2025 the BPCIA reached its fifteenth anniversary. In this CLE, we analyze the increasing amount of data available relating to patent litigation in the context of the BPCIA. We will look at trends relating to the number of asserted patents, portfolio composition, case timing and length, as well as outcomes. In addition, we survey Federal Circuit case law arising out of BPCIA action, and in particular issues decided in the recent multidistrict litigation on Eyelea.
Don’t Miss Out: Get Notified About Upcoming Life Sciences CLEs
Available Programming
Missed a prior session?
Email [email protected] to inquire about scheduling any of our prior programs for your team or organization. Select programs may be available for private viewing or customized in-house presentations.
Review of Enablement Standard Post-Amgen and Implications for Patent Claim Strategies and Litigation
Presented by Wan Chieh (Jenny) Lee and Kaitlin Farrell
During this webinar session, the panelists will briefly revisit the Supreme Court’s 2023 decision in Amgen v. Sanofi and dive into how the enablement standard has been applied post-Amgen. The panel will discuss the impact of Amgen and potential strategies for navigating the enablement requirement from drafting to litigation.
What You’ll Learn:
- The current state of the enablement standard post-Amgen
- Impact of the Amgen decision beyond antibody technology
- Potential drafting and litigation strategies for navigating the enablement requirement
Last-to-File Strategy: Defending Against Generic Attacks on Pediatric Exclusivity
Presented by Andrew Roper and Kaitlin Farrell
Pediatric Exclusivity provides a 6-month regulatory exclusivity period that may be added to the end of an Orange Book-listed patent term. While Pediatric Exclusivity has been described as “sweeping,” “amazingly powerful,” and “essentially ironclad,” in reality, it may not be so impervious to generic attacks.
This CLE explores a recent generic strategy–the “Last-to-File” strategy–that attempts to (i) circumvent a brand’s Pediatric Exclusivity, (ii) afford the Last-Filer generic exclusivity throughout the Pediatric Exclusivity term, and (iii) avoid patent damages, all without invalidating or establishing non-infringement of the listed patent(s).
Orange Book Patent Listings: Pressing Topics and Historical Perspectives
Presented by Andrew Wasson
The FTC has focused in on Orange Book listings as a potential hindrance to competition from generics manufacturers for many years. Hear from FDA Chair Andrew Wasson as he explores the evolution of Orange Book listing requirements, recent judicial decisions, as well as the effect of the FTC’s push for delisting on patent portfolios, due diligence reviews, and deal strategies following the decisions.
Program Faculty
Kaitlin Farrell, Partner
Kaitlin Farrell is a Partner in our New York office. Kaitlin’s practice focuses on complex patent and intellectual property litigation, with a particular emphasis on life sciences and pharmaceutical patent litigation.
Wan Chieh (Jenny) Lee, Partner
Wan Chieh (Jenny) Lee combines extensive experience across all aspects of patent law with a strong ability to analyze complex technical information to provide clients with business-oriented patent strategies and insights.
Andrew Roper, Partner
Andrew Roper is a partner in Haug Partners’ New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets.
Andrew Wasson, Partner
Andrew Wasson is a partner and Chair of Haug Partners’ FDA practice in the New York office. Andrew has a broad range of experience in both the brand and generic side of pharmaceuticals, especially with respect to issues involving intellectual property law and regulatory law.
